Actively Recruiting
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Led by Anhui Provincial Cancer Hospital · Updated on 2025-09-24
56
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
CONDITIONS
Official Title
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, male or female, with signed informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC)
- No prior systemic treatment for ES-SCLC
- At least one measurable chest lesion suitable for 15Gy/5 fractions irradiation
- Adequate blood and organ function
You will not qualify if you...
- Active leptomeningeal disease or untreated, uncontrolled brain metastases
- Prior treatment with immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies
- Received a live vaccine within 4 weeks before treatment
- Active or history of autoimmune diseases that may relapse
- Required systemic corticosteroids or immunosuppressive medications within 14 days before treatment
- History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases
- Severe chronic or active infections needing systemic antibacterial, antifungal, or antiviral therapy within 2 weeks before treatment, including tuberculosis
- Use of therapeutic oral or intravenous antibiotics within 2 weeks before starting treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Cancer Hospital
Hefei, Anhui, China, 230031
Actively Recruiting
Research Team
S
Shuanghu Yuan, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here